Pharma Mar
€70.75Change from previous close: −3.21%Absolute change: −€2.35
At a glance
- Revenue growth
- +26.61%
- 2025 vs 2024
- Net income growth
- +187.03%
- 2025 vs 2024
- Net margin
- 33.9%
- 2024: 14.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 395 | 350 | 341 | 393 | 368 |
| Current assets | 283 | 250 | 253 | 275 | 295 |
| Cash and equivalents | 17.8 | 63.2 | 60.0 | 150 | 113 |
| Short-term investments | 149 | 91.3 | 103 | 32.6 | 88.5 |
| Receivables | 39.4 | 34.7 | 27.6 | 29.3 | 50.9 |
| Inventory | 50.6 | 50.9 | 39.3 | 27.7 | 10.5 |
| Net property, plant and equipment | 60.1 | 57.8 | 34.5 | 33.2 | 26.9 |
| Other intangible assets | 1.4 | 1.0 | 1.2 | 1.2 | 1.1 |
| Long-term investments | 0.6 | 2.5 | 6.1 | 49.4 | 10.7 |
| Current liabilities | 93.9 | 82.7 | 95.9 | 97.3 | 86.3 |
| Accounts payable | 40.9 | 38.8 | 29.2 | 27.5 | 26.9 |
| Long-term debt | 35.6 | 39.9 | 27.0 | 25.9 | 33.4 |
| Total debt | 49.4 | 51.1 | 43.7 | 42.6 | — |
| Total liabilities | 143 | 141 | 147 | 170 | 190 |
| Total equity (incl. minority) | 252 | 208 | 193 | 223 | 178 |
| Retained earnings | 234 | 168 | 142 | 157 | 121 |